PMV Pharmaceuticals (PMVP) Price & Analysis

Compare

124 Followers

PMVP Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.81 - $1.82

Previous CloseN/A

Volume81.53K

Average Volume (3M)270.87K

Market Cap

$83.20M

Enterprise Value-$86.12M

Total Cash (Recent Filing)$142.27M

Total Debt (Recent Filing)$1.02M

Price to Earnings (P/E)―

Beta1.64

Next Earnings

Nov 06, 2025

EPS Estimate

-0.41

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding52,990,864

10 Day Avg. Volume244,402

30 Day Avg. Volume270,870

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-1.04

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit2.69K

Enterprise Value/Ebitda0.96

Forecast

1Y Price Target

$18.00

Price Target Upside1124.49% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsEnrollment into the pivotal Ph2 portion of the PYNNACLE trial evaluating rezatapopt monotherapy in TP53 Y220C and KRAS WT advanced solid tumors remains on track.

Financial PerformancePMV ended 2024 with $183.3M in cash, which should fund operations to end-2026.

Bears Say

Clinical Data RisksRisks include negative PC14586 clinical data and setbacks in later-stage studies.

PMV Pharmaceuticals News

PMV Pharmaceuticals reports Q2 EPS (41c), consensus (38c)

Cash, cash equivalents, and marketable securities of $148.3 million as of June 30, 2025, providing expected cash runway...

17d ago

PMVP

PMV Pharmaceuticals Reports Q2 2025 Financial Results

Pmv Pharmaceuticals, Inc. ( ($PMVP) ) has released its Q2 earnings. Here is a breakdown of the information...

16d ago

PMVP

PMV Pharmaceuticals Holds 2025 Annual Stockholder Meeting

An update from PMV Pharmaceuticals ( ($PMVP) ) is now available. On June 5, 2025, PMV Pharmaceuticals held...

3M ago

PMVP

PMV Pharmaceuticals Reports Q1 2025 Financial Results

Pmv Pharmaceuticals, Inc. ( ($PMVP) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

PMVP

PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)

“Our registrational PYNNACLE trial continues to progress well and enrollment remains on track,” said David Mack, Ph.D., President...

4M ago

PMVP

PMV Pharmaceuticals sees cash runway to end of 2026

PMV Pharma ended the first quarter with $165.8 million in cash, cash equivalents, and marketable securities, compared to...

4M ago

PMVP

Buy Recommendation for PMV Pharmaceuticals Driven by Financial Stability and Potential of Rezatapopt

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on PMVP stock, giving a Buy rating on...

5M ago

PMVP

PMV Pharmaceuticals Reports Progress in Clinical Trials

Pmv Pharmaceuticals, Inc. ( ($PMVP) ) has released its Q4 earnings. Here is a breakdown of the information...

6M ago

PMVP

PMV Pharmaceuticals sees cash runway to end of 2026

As of December 31, 2024, PMV Pharma had $183.3 million in cash, cash equivalents, and marketable securities, compared...

6M ago

PMVP

PMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)

“PMV demonstrated excellent execution in 2024 with the continued advancement of the pivotal, Phase 2 portion of the...

6M ago

PMVP

Pmv Pharmaceuticals, Inc. (PMVP) Q4 Earnings Cheat Sheet

Pmv Pharmaceuticals, Inc. (PMVP) is scheduled to report 4th quarter earnings on 02/26/2025. Regarding Q4 estimates, Wall Street...

6M ago

PMVP

PMV Pharmaceuticals files $200M mixed securities shelf

08:03 EST PMV Pharmaceuticals (PMVP) files $200M mixed securities shelf Published first on TheFly – the ultimate source...

9M ago

PMVP

PMV Pharmaceuticals upgraded at Oppenheimer ahead of rezatapopt readout

Oppenheimer upgraded PMV Pharmaceuticals (PMVP) to Outperform from Perform with a $6 price target after the company reported...

10M ago

PMVP

PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer

Oppenheimer upgraded PMV Pharmaceuticals (PMVP) to Outperform from Perform with a $6 price target Published first on TheFly...

10M ago

PMVP

PMVP FAQ

What was PMV Pharmaceuticals’s price range in the past 12 months?

PMV Pharmaceuticals lowest stock price was $0.81 and its highest was $1.82 in the past 12 months.

What is PMV Pharmaceuticals’s market cap?

PMV Pharmaceuticals’s market cap is $83.20M.

When is PMV Pharmaceuticals’s upcoming earnings report date?

PMV Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 74 days.

How were PMV Pharmaceuticals’s earnings last quarter?

PMV Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.383 by -$0.027.

Is PMV Pharmaceuticals overvalued?

According to Wall Street analysts PMV Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does PMV Pharmaceuticals pay dividends?

PMV Pharmaceuticals does not currently pay dividends.

What is PMV Pharmaceuticals’s EPS estimate?

PMV Pharmaceuticals’s EPS estimate is -0.41.

How many shares outstanding does PMV Pharmaceuticals have?

PMV Pharmaceuticals has 52,990,864 shares outstanding.

What happened to PMV Pharmaceuticals’s price movement after its last earnings report?

PMV Pharmaceuticals reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.383. Following the earnings report the stock price went down -4.605%.

Which hedge fund is a major shareholder of PMV Pharmaceuticals?

Currently, no hedge funds are holding shares in PMVP

PMV Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-45.57%

Trailing 12-Months

Asset Growth

-35.65%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

PMV Pharmaceuticals

PMV Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which are the most common mutations found in human cancers. The company operates within the healthcare and biotechnology sectors, aiming to provide transformative treatments that specifically target cancer's genetic drivers.

PMV Pharmaceuticals (PMVP) Earnings & Revenues

Historic Earnings Reports

PMVP Stock 12 Month Forecast

Average Price Target

$18.00

▲(1124.49% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","14":"$14","19":"$19","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4,9,14,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.4,2.676923076923077,3.953846153846154,5.230769230769232,6.507692307692308,7.784615384615385,9.061538461538463,10.338461538461539,11.615384615384617,12.892307692307694,14.16923076923077,15.446153846153848,16.723076923076924,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.4,2.676923076923077,3.953846153846154,5.230769230769232,6.507692307692308,7.784615384615385,9.061538461538463,10.338461538461539,11.615384615384617,12.892307692307694,14.16923076923077,15.446153846153848,16.723076923076924,{"y":18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.4,2.676923076923077,3.953846153846154,5.230769230769232,6.507692307692308,7.784615384615385,9.061538461538463,10.338461538461539,11.615384615384617,12.892307692307694,14.16923076923077,15.446153846153848,16.723076923076924,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.12,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >